A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Oct 2021
Historique:
received: 08 09 2021
revised: 06 10 2021
accepted: 11 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 30 12 2021
Statut: epublish

Résumé

Adenomatous polyps are precancerous lesions associated with a higher risk of colorectal cancer (CRC). Curcumin and anthocyanins have shown promising CRC-preventive activity in preclinical and epidemiological studies. The objective of this window-of-opportunity, proof-of principle trial was to evaluate the effect of curcumin combined with anthocyanin supplements on tissue biomarkers of colorectal adenomatous polyps. Eligible patients received either anthocyanin and curcumin supplementation or related matching placebo for 4-6 weeks before polyp removal. Adenomatous polyps and adjacent tissue biopsies were collected at baseline and after supplementation for immunohistochemical assessment of β-catenin, NF-kappa B (NF-κB), Ki-67, P53, and dysplasia. No differences were observed in baseline biomarker expression between normal and dysplastic tissues. The combination of anthocyanins and curcumin resulted in a significant borderline reduction of NF-κB immunohistochemistry (IHC) expression in adenoma tissue (geometric mean ratio (GMR): 0.72; 95% confidence interval (CI): 0.51-1.00;

Identifiants

pubmed: 34681684
pii: ijms222011024
doi: 10.3390/ijms222011024
pmc: PMC8539981
pii:
doi:

Substances chimiques

Anthocyanins 0
Ki-67 Antigen 0
NF-kappa B 0
Tumor Suppressor Protein p53 0
Curcumin IT942ZTH98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Cancer Research UK
ID : 13101
Pays : United Kingdom

Références

Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):5042-5046
pubmed: 30070343
Cancer Prev Res (Phila). 2011 Mar;4(3):354-64
pubmed: 21372035
Clin Cancer Res. 2002 Feb;8(2):314-46
pubmed: 11839647
J Sci Food Agric. 2012 Jul;92(9):1822-5
pubmed: 22555950
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Nutr Sci. 2013 Jul 24;2:e22
pubmed: 25191571
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Eur Rev Med Pharmacol Sci. 2016;20(4):762-6
pubmed: 26957282
Am J Clin Pathol. 1981 May;75(5):734-8
pubmed: 6165237
Adv Exp Med Biol. 2007;595:453-70
pubmed: 17569224
Molecules. 2020 Feb 19;25(4):
pubmed: 32093121
Front Biosci. 2008 Jan 01;13:2950-9
pubmed: 17981768
Mol Nutr Food Res. 2018 Aug;62(16):e1800267
pubmed: 29943914
J Appl Physiol (1985). 2018 Feb 1;124(2):330-340
pubmed: 28935827
J Am Coll Nutr. 2019 Jul;38(5):470-477
pubmed: 30589398
Cancer Lett. 2016 Apr 10;373(2):227-33
pubmed: 26850372
Drug Metab Dispos. 2001 Dec;29(12):1521-4
pubmed: 11717168
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7
pubmed: 18559556
Sci Rep. 2019 Jul 17;9(1):10338
pubmed: 31316146
Int J Cancer. 2020 Aug 15;147(4):1027-1039
pubmed: 31945199
Cancer Chemother Pharmacol. 2007 Jul;60(2):171-7
pubmed: 17051370
Cancer Prev Res (Phila). 2013 Feb;6(2):119-28
pubmed: 23233733
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
J Immunol. 1999 Sep 15;163(6):3474-83
pubmed: 10477620
Int J Mol Sci. 2020 Sep 08;21(18):
pubmed: 32911639
Food Chem. 2016 Mar 1;194:1275-82
pubmed: 26471682
J Nat Prod. 2011 Apr 25;74(4):664-9
pubmed: 21413691
Mol Nutr Food Res. 2021 Jul;65(13):e2000977
pubmed: 34015183
Bioorg Med Chem. 2014 Jan 1;22(1):435-9
pubmed: 24280069
Drug Res (Stuttg). 2017 Apr;67(4):244-251
pubmed: 28158893
Clin Ophthalmol. 2010 Oct 21;4:1201-6
pubmed: 21060672
Int J Mol Sci. 2020 Mar 29;21(7):
pubmed: 32235371
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
Biomed Chromatogr. 2011 Jun;25(6):660-3
pubmed: 20812200
Cancer Lett. 2008 Oct 8;269(2):281-90
pubmed: 18571839
Cancer Prev Res (Phila). 2009 Jul;2(7):625-33
pubmed: 19584076
Eur Rev Med Pharmacol Sci. 2017 May;21(10):2518-2525
pubmed: 28617532

Auteurs

Irene Maria Briata (IM)

Division of Medical Oncology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Laura Paleari (L)

Research, Innovation and HTA, A.Li.Sa. Liguria Health Authority, 16121 Genoa, Italy.

Mariangela Rutigliani (M)

Division of Pathology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Marilena Petrera (M)

Division of Medical Oncology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Silvia Caviglia (S)

Clinical Trial Unit, Office of the Scientific Director, E.O. Galliera Hospital, 16128 Genoa, Italy.

Paola Romagnoli (P)

Division of Gastroenterology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Mauro Dalla Libera (MD)

Division of Gastroenterology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Massimo Oppezzi (M)

Division of Gastroenterology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Matteo Puntoni (M)

Clinical & Epidemiological Research Unit, University Hospital of Parma, 43126 Parma, Italy.

Giacomo Siri (G)

Division of Pathology, E.O. Galliera Hospital, 16128 Genoa, Italy.

Matteo Lazzeroni (M)

Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.

Lynne Howells (L)

Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, UK.

Raj Singh (R)

Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, UK.

Karen Brown (K)

Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, UK.

Andrea DeCensi (A)

Division of Medical Oncology, E.O. Galliera Hospital, 16128 Genoa, Italy.
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London E1 4NS, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH